| Recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable NCT05896839 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Suspended | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 In NCT05764395 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Can NCT04593277 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa- NCT05393713 | Mayo Clinic | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment i NCT04708418 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma NCT04967196 | Mayo Clinic | Phase 1 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Bone Loss in Melanoma Survivors Receiving Immunotherapy NCT04516122 | M.D. Anderson Cancer Center | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma NCT04356729 | Elizabeth Buchbinder, MD | Phase 2 |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Mela NCT05907512 | Fudan University | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immuno NCT04990726 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma NCT03727789 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Exami NCT03677739 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and Aft NCT03698019 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma NCT03554083 | Mayo Clinic | Phase 2 |
| Completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melano NCT03033576 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizuma NCT02506153 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe NCT02224781 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Active Not Recruiting | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mut NCT01989585 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |